Normal-tissue toxicities of thoracic radiation therapy: Esophagus, lung, and spinal cord as organs at risk

Hematology/Oncology Clinics of North America

Volumn 18, Issue 1, 2004, Pages 131-160

  Werner Wasik, Maria ^a   Yu, Xiaoli ^b   Marks, Lawrence B ^b   Schultheiss, Timothy E ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; MITOMYCIN C;

BRONCHOMALACIA; BRONCHUS STENOSIS; CANCER RADIOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; ESOPHAGITIS; HUMAN; INCIDENCE; LUNG DISEASE; MEDIASTINUM DISEASE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; REVIEW; RISK FACTOR; SPINAL CORD DISEASE;

EID: 1042298063     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(03)00150-3     Document Type: Review

References (145)

1. Phillips T.L., Ross G. Time-dose relationships in the mouse esophagus. Radiology. 113:1974;435-440.
2. Goldstein H.M., Rogers L.F., Fletcher G.H., Dodd G.D. Radiological manifestations of radiation-induced injury to the normal upper gastrointestinal tract. Radiology. 117:1975;135-140.
3. Lepke R.A., Libshitz H.I. Radiation-induced injury of the esophagus. Radiology. 148:1983;375-378.
4. Werner-Wasik M., Scott C., Curran W.J. Jr., Byhardt R. Correlation between acute esophagitis and late pneumonitis in patients (pts) with locally advanced non-small cell lung cancer (LA-NSCLC) receiving concurrent thoracic radiotherapy (RT) and chemotherapy: a multivariate analysis of the Radiation Therapy Oncology Group (RTOG) database [abstract]. Proc Am Soc Clin Oncol. 21:2002;299a. Abstract 1192.
5. Cox J.D., Pajak T.F., Asbell S., Russell A.H., Pederson J., Byhardt R.W.et al. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 RTOG trials. Int J Radiat Oncol Biol Phys. 27:1993;493-498.
6. Hirota S., Tsujino K., Hishikawa Y., Watanabe H., Kono K., Soejima T.et al. Endoscopic findings of radiation esophagitis in concurrent chemoradiotherapy for intrathoracic malignancies. Radiother Oncol. 58:2001;273-278.
7. Werner-Wasik M., Axelrod R.S., Friedland D.P., Hauck W., Rose L.J., Chapman A.E.et al. Preliminary report on reduction of esophagitis by amifostine in patients with non-small-cell lung cancer treated with chemoradiotherapy. Clin Lung Cancer. 2(4):2001;284-289.
8. Werner-Wasik M., Axelrod S.A., Friedland D.P., Hauck W., Rose L.J., Chapman A.E.et al. Phase II trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemotherapy. Semin Radiat Oncol. 12(Suppl 1):2002;34-39.
9. Rowland M., Tozer T. Assessment of area under the curve. Rowland M., Tozer T.N., Rowland R. Clinical pharmacokinetics. Concepts and applications. 3rd edition:1995;469-472 Williams and Wilkins, Baltimore (MD).
10. Movsas B. Exploring the role of the radioprotector amifostine in locally advanced non-small cell lung cancer: Radiation Therapy Oncology Group trial 98-01. Semin Radiat Oncol. 12(Suppl 1):2002;40-45.
11. Gaspar L.E., Gandara D.R., Chansky K., Albain K.S., Lara P.N. Jr., Crowley J.J.et al. Consolidation docetaxel following concurrent chemoradiotherapy in pathologic stage IIIb non-small cell lung cancer (NSCLC) (SWOG 9504): patterns of failure and updated survival [abstract]. Proc Am Soc Clin Oncol. 20:2001;315a. Abstract 1255.
12. Curran W. Jr., Scott C., Langer C., Komaki R., Lee J., Hauser B.et al. Phase III comparison of sequential vs. concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer: initial report of RTOG 9410 [abstract]. Proc Am Soc Clin Oncol. 19:2000;484a.
13. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S.et al. Phase III study of concurrent vs. sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol. 17:1999;2692-2699.
14. Boal D.K., Newburger P.E., Teele R.L. Esophagitis induced by combined radiation and adriamycin. AJR Am J Roentgenol. 132:1979;567-570.
15. Vokes E.E., Leopold K.A., Herndon J.E., Crawford J., Perry M.C., Miller A.A.et al. A randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy and concomitant chemoradiotherapy for unresectable stage III non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol. 18:1999;459a.
16. Werner-Wasik M., Pequignot E., Leeper D., Hauck W., Curran W. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with non-operative therapy. Int J Radiat Oncol Biol Phys. 48:2000;689-696.
17. Ball D., Bishop J., Smith J., Crennan E., O'Brien P., Davis S.et al. A phase III study of accelerated radiotherapy with and without carboplatin in non-small cell lung cancer: an interim toxicity analysis of the first 100 patients. Int J Radiat Oncol Biol Phys. 31:1995;267-272.
18. Choy H., LaPorte K., Knill-Selby E., Mohr P., Shyr Y. Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Sem Rad Oncol. 9:1999;90-96.
19. Langer C.J. Concurrent chemoradiation using pacltaxel and carboplatin in locally advanced non-small cell lung cancer. Sem Rad Oncol. 9:1999;108-116.
20. Michalowski A., Hornsey S. Assays of damage to the alimentary canal. Br J Cancer. 53(Suppl VII):1986;1-6.
21. Dubray B., Livartowski A., Beuzeboc P., Pouillart P., Cosset J.M. Combined chemoradiation for locally advanced non-small cell lung cancer. J Infus Chemother. 5:1995;195-196.
22. Saunders M.I., Dische S., Barrett A., Parmar M.K.B., Harvey A., Gibson D. Randomized multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small cell lung cancer: an interim report. Br J Cancer. 73:1996;1455-1462.
23. Byhardt R.W., Scott C., Sause W.T., Emami B., Komaki R., Fisher B.et al. Response, toxicity, failure patterns, and survival in five RTOG trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 42:1998;469-478.
24. Werner-Wasik M., Scott C., Graham M.L., Smith C., Byhardt R.W., Roach M.et al. Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients. Int J Radiat Oncol Biol Phys. 44:1999;327-331.
25. Umsawasdi T., Valdivieso M., Barkley H.T., Booser D.J., Chiuten D.F., Murphy W.K.et al. Esophageal complications from combined chemoradiotherapy (cyclophosphamide + adriamycin + cisplatin + XRT) in the treatment of non-small cell lung cancer. Int J Rad Oncol Biol Phys. 11:1985;511-519.
26. Emami B. Three-dimensional conformal radiation therapy in bronchogenic carcinoma. Semin Radiat Oncol. 6:1996;92-97.
27. Maguire P.D., Sibley G.S., Zhou S.M., Jamieson T.A., Light K.L., Antoine P.et al. Clinical and dosimetric predictors of radiation-induced esophageal toxicy. Int J Radiat Oncol Biol Phys. 45(1):1999;97-103.
28. Hirota S., Tsujino K., Endo M., Kotani Y., Satouchi M., Kado T.et al. Dosimetric predictors of radiation esophagitis in patients treated for non-small cell lung cancer with carboplatin/paclitaxel radiotherapy. Int J Radiat Oncol Biol Phys. 51:2001;291-295.
29. Singh A.K., Lockett M.A., Bradley J.D. Predictors of radiation-induced esophageal toxicity in patients with non-small cell lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 55:2003;337-341.
30. Fletcher G. Clinical dose-response curves of human malignant epithelial tumors. Br J Radiol. 46:1973;1-12.
31. Hayman J.A., Martel M.K., Ten Haken R.K., Normolle D.P., Todd R.F., Littles J.F.et al. Dose escalation in non-small cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol. 19:2001;127-136.
32. Graham M.V., Matthews J.W., Harms W.B., Emami B., Glazer H.S., Purdy J.A. Three-dimensional radiation treatment planning study for patients with carcinoma of the lung. Int J Radiat Oncol Biol Phys. 29:1994;1105-1117.
33. DeGersem W.R.T., Derycke S., DeWagter C., DeNeve W.C.J. Optimization of beam weights in conformal radiotherapy planning of stage III non-small cell lung cancer: effects on the therapeutic ratio. Int J Radiat Oncol Biol Phys. 47(1):2000;255-260.
34. Derycke S., DeGersem W.R., Van Dyuse B.B.R., De Neve W.C.J. Conformal radiotherapy of stage III non-small cell lung cancer: a class solution involving non-coplanar intensity-modulated beams. Int J Radiat Oncol Biol Phys. 41(4):1998;771-777.
35. Xiao Y., Werner-Wasik M., Michalski D., Houser C., Bednarz G., Curran W. Jret al. Comparison of three IMRT-based treatment techniques allowing partial esophagus sparing in patients receiving thoracic radiation therapy for lung cancer. 2002;American Society for Therapeutic Radiology and Oncology (ASTRO), New Orleans (LA).
36. Emami B., Scott C., Byhardt R., Graham M.V., Andras E.J., John M.et al. The value of regional nodal radiotherapy (dose/volume) in the treatment of unresectable non-small cell lung cancer: an RTOG analysis. Int J Radiat Oncol Biol Phys. 36(Suppl l):1996;209.
37. Emami B., Lyman J., Brown A., Coia L., Goitein M., Munzenrider J.E.et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 21(1):1991;109-122.
38. Brizel D.M., Wasserman T.H., Henke M., Strnad V., Monnier A., Eschwege F.et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 18:2000;3339-3345.
39. Ito H., Meistrich M.L., Barkley H.T. Jr., Thames H.D. Jr., Milas L. Protection of acute and late radiation damage of the gastrointestinal tract by WR-2721. Int J Radiat Oncol Biol Phys. 12(2):1986;211-219.
40. Koukourakis M., Hlouverakis G., Kosma L., Skarlatos J., Damilakis J., Giatromanolaki A.et al. The impact of overall treatment time on the results of radiotherapy for non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 34:1996;315-322.
41. Antonadou D., Coliarakis N., Synodinou M., Athanassiou H., Kouveli A., Verigos C.et al. Randomized phase III trial of radiation treatment plus/minus amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys. 51:2001;915-922.
42. Komaki R., Lee J.S., Kaplan B., Allen P., Kelly J.F., Liao Z.et al. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage I-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol. 12(Suppl 1):2002;46-49.
43. McGinnis W.L., Loprinzi C.L., Buskirk S.J., Sloan J.A., Drummond R.G., Frank A.R.et al. Placebo-controlled trial of sucralfate for inhibiting radiation-induced esophagitis. J Clin Oncol. 15:1997;1239-1243.
44. Stickle R.L., Epperly M.W., Klein E., Bray J., Greenberger J. Prevention of irradiation-induced esophagitis by plasmid/liposome delivery of the human manganese superoxide dismutase transgene. Radiat Oncol Invest. 7:1999;204-217.
45. Spielberegr R.T., Stiff B., Emmanouilides C., Yanovich S., Bensinger W., Hedrick E.et al. Efficacy of recombinant human keratinocyte growth factor in reducing mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation after radiation-based conditioning: results of a phase II trial [abstract]. Proc Am Soc Clin Oncol. 20:2001;7. Abstract 25.
46. Favaretto A., Paccagnella A., Tomio L., Sartori F., Cipriani A., Zuin R.et al. Pre-operative chemoradiotherapy in non-small cell lung cancer stage III patients. Feasibility, toxicity and long-term results of a phase II study. Eur J Cancer. 32A:1996;2064-2069.
47. Segawa Y., Takigawa N., Kataoka M., Takata I., Fujimoto N., Ueoka H. Risk factors for development of radiation pneumonitis following radiation therapy with or without chemotherapy for lung cancer. Int J Radiat Oncol Biol Phys. 39:1997;91-98.
48. Fu X.L., Jiang G.L., Wang L.J., Qian H., Fu S., Yie M.et al. Hyperfractionated accelerated radiation therapy for non-small cell lung cancer: clinical phase I/II trial. Int J Radiat Oncol Biol Phys. 39:1997;545-552.
49. Monson J., Stark P., Reilly J., Sugarbaker D., Strauss G., Swanson S.et al. Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma. Cancer. 82:1998;842-850.
50. Yamada M., Kudoh S., Hirata K., Nakajima T., Yoshikawa J. Risk factors of pneumonitis following chemoradiotherapy for lung cancer. Eur J Cancer. 34:1998;71-75.
51. Nyman J., Bergman B., Mercke C. Accelerated hyperfractionated radiotherapy combined with induction and concomitant chemotherapy for inoperable non-small-cell lung cancer. Acta Oncol (Madr). 37:1998;539-545.
52. Van den Brande P., De Ruysscher D., Vansteenkiste J., Spaas P.h., Specenier P., Demedts M. Sequential treatment with vindesine-ifosfamide- platinum (VIP) chemotherapy followed by platinum sensitized radiotherapy in stage IIIB non-small cell lung cancer: a phase II trial. Lung Cancer. 22:1998;45-53.
53. Makimoto T., Tsuchiya S., Hayakawa K., Saitoh R., Mori M. Risk factors for severe radiation pneumonitis in lung cancer. Jpn J Clin Oncol. 29:1998;192-197.
54. Graham M., Purdy J., Emami B., Harms W., Bosch W., Lockett M.et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 45:1999;323-329.
55. Robnett T., Machtay M., Vines E., McKenna M., Algazy K., McKenna W. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys. 48:2000;89-94.
56. Sunyach M., Falchero L., Pommier P., Perol M., Appin D., Vincent M.et al. Prospective evaluation of early lung toxicity following three-dimensional conformal radiation therapy in non-small-cell lung cancer: preliminary results. Int J Radiat Oncol Biol Phys. 48:2000;459-463.
57. Inoue A., Kunitoh H., Sekine I., Sumi M., Tokuuye K., Saijo N. Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. Int J Radiat Oncol Biol Phys. 49:2001;649-655.
58. Hernando M., Marks L., Bentel G., Zhou S.M., Hollis D., Das S.et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys. 51:2001;650-659.
59. Oetzel D., Schraube P., Hensley F., Sroka-Perez G., Menke M., Flentje M. Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys. 33:1995;455-460.
60. Perry M., Eaton W.L., Propert K.J., Ware J.H., Zimmer B., Chahinian A.P.et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med. 316:1987;912-918.
61. Gross N.J. Pulmonary effects of radiation therapy. Ann Intern Med. 86:1977;81-92.
62. Simpson J.R., Francis M.E., Perez-Tamayo R., Marks R.D., Rao D.V. Palliative radiotherapy for inoperable carcinoma of the lung: final report of a RTOG multi-institutional trial. Int J Radiat Oncol Biol Phys. 11:1985;751-758.
63. Kwon H.C., Kim S.K., Chung W.K., Cho M.J., Kim J.S., Kim J.S.et al. Effect of pentoxifylline on radiation response of non-small cell lung cancer: a phase III randomized multicenter trial. Radiother Oncol. 56:2000;175-179.
64. Perez C.A., Stanley K., Rubin P., Kramer S., Brady L.W., Marks J.E.et al. A prospective randomized study of various radiation doses and fractionation schedules in the treatment of inoperable non-small cell carcinoma of the lung. Cancer. 45:1980;2744-2753.
65. Martel M., Ten Haken R., Hazuka M., Turrisi A., Fraass B., Lichter A. Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. Int J Radiat Oncol Biol Phys. 28:1994;575-581.
66. Choi N., Kanarek D.J., Grillo H. Effect of post-operative radiotherapy on changes in pulmonary function in patients with stage II and IIIa lung carcinoma. Int J Radiat Oncol Biol Phys. 18:1990;95-99.
67. Brady L.W., Germon P.A., Cander L. The effects of radiation therapy on pulmonary function in carcinoma of the lung. Radiology. 85:1965;130-134.
68. Bentzen S.M., Skoczylas J.Z., Overgaard M., Overgaard M., Overgaard J. Radiotherapy-related lung fibrosis enhanced by Tamoxifen. J Nat Cancer Inst. 88:1996;918-922.
69. Levinson B., Marks L.B., Munley M.T., Poulson J., Hollis D., Jaszczak R.et al. Regional dose response to pulmonary irradiation using a manual method. Radiother Oncol. 48:1998;53-60.
70. Marks L.B. The pulmonary effects of thoracic irradiation. Oncology. 8:1994;89-100.
71. Morgan G., Pharm B., Breit S. Radiation and the lung: a reevaluation of the mechanisms mediating pulmonary injury. Int J Radiat Oncol Biol Phys. 31:1995;361-369.
72. Abid S., Malhotra V., Perry M. Radiation-induced and chemotherapy- induced pulmonary injury. Curr Opin Oncol. 13:2001;242-248.
73. Garipagaoglu M., Munley M.T., Hollis D., Poulson J.M., Bentel G.C., Sibley G.et al. The effect of patient-specific gactors on tadiation induced regional lung injury. Int J Radiat Oncol Biol Phys. 45:1999;331-338.
74. Maguire P.D., Marks L.B., Sibley G.S., Herndon J.E., Clough R.W., Light K.L.et al. 73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer. J Clin Oncol. 19:2001;705-711.
75. Dechambre S., Dorzee J., Fastrez J., Hanzen C., van Houtte P., d'Odemout J.P. Bronchial stenosis and sclerosing mediastintis: an uncommon complication of external thoracic rediotherapy. Eur Respir J. 11:1998;1188-1190.
76. von der Maase H., Overgaard J., Vaeth M. Effect of cancer chemotherapeutic drugs on radiation-induced lung damage in mice. Radiother Oncol. 5:1986;245-257.
77. Sause W.T., Scott C., Taylor S., Johnson D., Livingston R., Komaki R.et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 87(3):1995;198-205.
78. Clamon G., Herndon J., Cooper R., Chang A.Y., Rosenman J., Green M.R. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol. 17(1):1999;4-11.
79. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S.et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 17(9):1999;2692-2699.
80. Schaake-Koning C., van den Bogaert W., Dalesio O., Festen J., Hoogenhout J., van Houtte P.et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 326(8):1992;524-530.
81. Mattson K., Holsti L.R., Poppius H., Korhola O., Stenman S., Tammilehto L.et al. Radiation pneumonitis and fibrosis following split-course radiation therapy for lung cancer: a radiologic and physiologic study. Acta Oncol. 26:1987;193-196.
82. Rubenstein J.H., Richter M.P., Moldofsky P.J., Solin L.J. Prospective prediction of post-radiation therapy lung function using quantitative lung scans and pulmonary function testing. Int J Radiat Oncol Biol Phys. 15:1988;83-87.
83. Robert F., Childs H.A., Spencer S.A., Redden D.T., Hawkins M.M. Phase I/IIa study of concurrent paclitaxel and cisplatin with radiation therapy in locally advanced non-small cell lung cancer: analysis of early and late pulmonary morbidity. Semin Ratiat Oncol. 9:1999;136-147.
84. Bonnet R.B., Bush D., Cheek G.A., Slater J.D., Panossian D., Franke C.et al. Effects of proton and combined proton/ photon beam radiation on pulmonary function on patients with resectable but medically inoperable non-small cell lung cancer. Chest. 120:2001;1803-1810.
85. Rosen I.I., Fischer T.A., Antolak J.A., Starkschall G., Travis E.L., Tucker S.L.et al. Correlation between lung fibrosis and radiation therapy dose after concurrent radiation therapy and chemotherapy for limited small cell lung cancer. Radiology. 221(3):2001;614-622.
86. Trask C.W., Joannides T., Harper P.G., Tobias J.S., Spiro S.G., Geddes D.M.et al. Radiation-induced lung fibrosis after treatment of small cell carcinoma of the lung with very high-dose cyclophosphamide. Cancer. 55(1):1985;57-60.
87. Woel R.T., Munley M.T., Hollis D., Fan M., Bentel G., Anscher M.S.et al. The time course of radiation therapy-induced reductions in regional perfusion: a prospective study with > 5 years of follow-up. Int J Radiat Oncol Biol Phys. 52:2002;58-67.
88. Seppenwoolde Y., Muller S.H., Theuws J., Baas P., Belderbos J.S., Boersma L.J.et al. Radiation dose-effect relations and local recovery in perfusion for patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 47:2000;681-691.
89. Yorke E.D., Jackson A., Rosenzweig K.E., Merrick S.A., Gabrys D., Venkatraman E.S.et al. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 54:2002;329-339.
90. Lind P., Marks L.B., Hollis D., Fan M., Zhou S.M., Munley M.T.et al. Receiver operator curves (ROC) analysis of predictors for radiation-induced symptomatic lung injury. Int J Radiat Oncol Biol Phys. 54(2):2002;340-347.
91. Anscher M., Kong F., Andrews K., Clough R., Marks L.B., Bentel G.et al. Plasma transforming growth factor β1 as a predictor of radiation pneumonitis. Int J Radiat Onc Biol Phys. 41:1998;1029-1036.
92. Chen Y., Williams J., Ding I., Hernady E., Liu W., Smudzin T.et al. Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol. 12(1 Suppl 1):2002;26-33.
93. Haston C.K., Travis E.L. Murine susceptibility to radiation-induced pulmonary fubrosis is induced by a genetic factor implicated in susceptibility to bleomycin-induced pulmonary fibrosis. Cancer Res. 57:1997;5286-5291.
94. Schultheiss T.E., Stephens L.C., Peters L.J. Survival in radiation myelopathy. Int J Radiat Oncol Biol Phys. 12(10):1986;1765-1769.
95. Holdorff B. Dose effect relationships in cervical and thoracic radiation myelopathies. Acta Radiologica Oncol. 19(6):1980;271-277.
96. Schultheiss T.E., Higgins E.M., El-Mahdi A.M. The latent period in clinical radiation myelopathy. Int J Radiat Oncol Biol Phys. 10(7):1984;1109-1115.
97. Feldmann E., Posner J.B. Episodic neurologic dysfunction in patients with Hodgkin's disease. Arch Neurol. 43:1986;1227-1233.
98. Chouchair A.K. Myelopathies in the cancer patient: incidence, presentation, diagnosis and management. Oncology. 5:1991;25-37.
99. Zulch K.J., Oeser H. Delayed spinal radionecrosis - a juridical error? Neuroradiology. 8:1974;173-176.
100. Abadir R. Radiation myelitis: can diagnosis be unequivocal without histological evidence? Int J Radiat Oncol Biol Phys. 6(5):1980;649-650.
101. Lechevalier B., Humeau G., Houtteville J.P. Myelopathies radiotherapiques "hypertrophiantes" a propos de cinq observations dont une anatomo-clinique. Revue Neurologique Paris. 129:1973;119-132.
102. Marty R., Minckler D.S. Radiation myelitis simulating tumor. Arch Neurol. 29:1973;352-354.
103. Kitamura H., Kameda Y., Yoshimura Y., Nagaoka S., Takai S., Nagatsuka A. Delayed radiation myelopathy. Yokohama Med Bull. 30:1979;61-69.
104. Worthington B.S. Diffuse cord enlargement in radiation myelopathy. Clin Radiol. 30(1):1979;117-119.
105. Dorfman L.J., Donaldson S.S., Gupta P.R., Bosley T.M. Electrophysiologic evidence of subclinical injury to the posterior columns of the human spinal cord after therapeutic radiation. Cancer. 50:1982;2815-2819.
106. Snooks S.J., Swash M. Motor conduction velocity in the human spinal cord: slowed conduction in multiple sclerosis and radiation myelopathy. J Neurol Neurosurg Psychiatry. 48(11):1985;1135-1139.
107. Wang P.Y., Shen W.C., Jan J.S. MR imaging in radiation myelopathy. AJNR Am J Neuroradiol. 13(4):1992;1049-1055.
108. Schultheiss T.E., Stephens L.C., Maor M.H. Analysis of the histopathology of radiation myelopathy. Int J Radiat Oncol Biol Phys. 14(1):1988;27-32.
109. van der Kogel A.J. The nervous system: radiobiology and experimental pathology. Scherer E., Streffer C., Trott K.-R. Radiopathology of organs and tissues. 1991;191-212 Springer-Verlag, Berlin.
110. Calvo W., Hopewell J.W., Reinhold H.S., Yeung T.K. Time and dose-related changes in the white matter of the rat brain after single doses of X-rays. Br J Radiol. 61:1988;1043-1052.
111. Reinhold H.S., Calvo W., Hopewell J.W., van den Berg A.P. Development of blood vessel-related radiation damage in the fimbria of the central nervous system. Int J Radiat Oncol Biol Phys. 18:1990;37-42.
112. Hubbard B.M., Hopewell J.W. Changes in the neuroglial cell populations of the rat spinal cord after local X-irradiation. Br J Radiol. 52:1979;816-821.
113. Myers R., Rogers M.A., Hornsey S.A. Reappraisal of the roles of glial and vascular elements in the development of white matter necrosis in irradiated rat spinal cord. Br J Cancer. 53:1986;221-223.
114. Verity G.L. Tissue tolerance: central nervous system. Radiology. 91(6):1968;1221-1225.
115. Baekmark U.B. Neurologic complications after irradiation of the cervical spinal cord for malignant tumour of the head and neck. Acta Radiol Ther Phys Biol. 14(1):1975;33-41.
116. Kim Y.H., Fayos J.V. Radiation tolerance of the cervical spinal cord. Radiology. 139(2):1981;473-478.
117. Kramer S. The hazards of therapeutic irradiation of the central nervous system. Clin Neurosurg. 15:1968;301-318.
118. Marks R.D., Agarwal S.K., Constable W.C. Increased rate of complication as a result of treating only one prescribed field daily. Radiology. 107:1972;615-619.
119. Schultheiss T.E., Kun L.E., Ang K.K., Stephens L.C. Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys. 31(5):1995;1093-1112.
120. Schultheiss T.E., Hanks G.E. The radiation dose response of the human cervical spinal cord. Int J Radiat Oncol Biol Phys. 45(Suppl):1999;174-175.
121. Schultheiss T.E., Stephens L.C., Jiang G.L., Ang K.K., Peters L.J. Radiation myelopathy in primates treated with conventional fractionation. Int J Radiat Oncol Biol Phys. 19(4):1990;935-940.
122. Knowles J.F. The radiosensitivity of the guinea pig spinal cord to X-rays: the effect of retreatment at one year and the effect of age at the time of irradiation. Int J Radiat Biol. 44:1983;433-442.
123. Dische S., Saunders M.I. Continuous hyperfractionated accelerated radiotherapy (CHART): an interim report upon late morbidity. Radioth Oncol. 16:1989;67-74.
124. Wong C.S., Van Dyk J., Simpson W.J. Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol. 20(1):1991;3-9.
125. Thames H.D. Repair kinetics in tissues: alternative models. Radiother Oncol. 14:1989;321-327.
126. Thames H.D., Ang K.K., Stewart F.A., van der Schueren E. Does incomplete repair explain the apparent failure of the basic LQ model to predict spinal cord and kidney responses to low doses per fraction? Int J Radiat Biol. 55:1988;27-43.
127. Marcus R.G., Million R.R. The incidence of myelitis after irradiation of the cervical spinal cord. Int J Radiat Oncol Biol Phys. 19:1990;3-8.
128. Ang K.K., van der Kogel A.J., van der Sschueren E. The effect of small radiation doses on the rat spinal cord: the concept of partial tolerance. Int J Radiat Oncol Biol Phys. 9:1983;1487-1491.
129. Hornsey S., White A. Isoeffect curve for radiation myelopathy. Br J Radiol. 53:1980;168-169.
130. Masuda K., Reid B.O., Withers H.R. Dose effect relationship for epilation and late effects on spinal cord in rats exposed to gamma rays. Radiology. 122:1977;239-242.
131. van der Kogel A.J. Radiation tolerance of the rat spinal cord: time-dose relationships. Radiology. 122(2):1977;505-509.
132. van der Kogel A.J. Central nervous system radiation injury in small animal models. Gutin P.H., Leibel S.A., Sheline G.E. Radiation injury to the nervous system. 1991;91-111 Raven Press, New York.
133. Wong C.S., Minkin S., Hill R.P. Linear-quadratic model underestimates sparing effect of small doses per fraction in rat spinal cord. Radiother Oncol. 23(3):1992;176-184.
134. Stephens L.C., Hussey D.H., Raulston G.L., Jardine J.H., Gray K.N., Almond P.R. Late effects of 50 MeV d leads to Be neutron and cobalt-60 irradiation of rhesus monkey cervical spinal cord. Int J Radiat Oncol Biol Phys. 9(6):1983;859-864.
135. Schultheiss T.E., Stephens L.C., Ang K.K., Price R.E., Peters L.J. Volume effects in rhesus monkey spinal cord. Int J Radiat Oncol Biol Phys. 29(1):1994;67-72.
136. Schultheiss T.E., Stephens L.C., Ang K.K., Jardine J.H., Peters L.J. Neutron RBE for primate spinal cord treated with clinical regimens. Radiat Res. 129(2):1992;212-217.
137. Austin J.P., Urie M.M., Cardenosa G., Munzenrider J.E. Probable causes of recurrence in patients with chordoma and chondrosarcoma of the base of skull and cervical spine. Int J Radiat Oncol Biol Phys. 25(3):1993;439-444.
138. Ang K.K., Jiang G.L., Feng Y., Stephens L.C., Tucker S.L., Price R.E. Extent and kinetics of recovery of occult spinal cord injury. Int J Radiat Oncol Biol Phys. 50(4):2001;1013-1020.
139. Coy R., Dolman C.L. Radiation myelopathy in relation to oxygen level. Br J Radiol. 44:1971;705-707.
140. van den Brenk H.A.S., Richter W., Hurley R.H. Radiosensitivity of the human spinal cord based on analysis of 357 cases receiving 4 MeV X rays in hyperbaric oxygen. Br J Radiol. 41:1968;205-214.
141. Dische S., Saunders M.I., Warburton M.F. Hemoglobin, radiation, morbidity and survival. Int J Radiat Oncol Biol Phys. 12(8):1986;1335-1337.
142. Asscher A.W., Anson S.G. Arterial hypertension and irradiation damage to the nervous system. Lancet. ii:1992;1343-1346.
143. Hopewell J.W., Wright E.A. The nature of latent cerebral irradiation damage and its modification by hypertension. Br J Radiol. 43:1970;161-167.
144. Bradley J.D., Graha M.V., Winter K.W., Purdy J.A., Komaki R., Roa W.H.et al. Acute and late toxicity results of RTOG 9311: a dose escalation study using 3D conformal radiation therapy in patients with inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 57(2 Suppl):2003;S137-S138.
145. Werner-Wasik M., Scott C., Movsas B., Langer C., Sarna L., Nicolaou N.et al. Amifostine as mucosal protectant in patients with locally advanced non-small cell lung cancer receiving intensive chemotherapy and thoracic radiotherapy. Int J Radiat Oncol Biol Phys. 57(2 Suppl):2003;S216.